Conjugated Estrogens/Bazedoxifene (Duavee): A Novel Agent for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause And the Prevention of Postmenopausal Osteoporosis
- PMID: 25798038
- PMCID: PMC4357350
Conjugated Estrogens/Bazedoxifene (Duavee): A Novel Agent for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause And the Prevention of Postmenopausal Osteoporosis
Abstract
Conjugated estrogens/bazedoxifene (Duavee): a novel agent for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis.
References
-
- North American Menopause Society. Menopause Practice: A Clinician’s Guide. 4th ed. Mayfield Heights, Ohio: North American Menopause Society; 2010. Overview of menopause; pp. 1–5.
-
- De Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013;16(3):316–337. - PubMed
-
- Goodman NF, Cobin RH, Ginzburg SB, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. 2011. Available at: www.aace.com/sites/default/files/menopause.pdf. Accessed October 10, 2014. - PubMed
-
- Office on Women’s Health, U.S. Department of Health and Human Services. Menopause. Sep, 2010. Available at http://www.womenshealth.gov/menopause/menopause-basics/index.html. Accessed October 10, 2014.
LinkOut - more resources
Full Text Sources